Elmeri Jokinen

Aurlide is a Finnish service provider in computer-aided drug discovery. We generate multiple hit series with excellent developability profiles - which is also one of the most important ways of early de-risking of preclinical development. In addition to designing structurally novel hits, we have contributed to solving ADME/PK related liabilities of our clients' lead molecules. We have improved compounds that had issues with, for example, metabolic stability, BBB permeability, and selectivity. Resolving unknown binding sites, targets or mechanisms of action of bioactive molecules is also within the scope of our expertise. In addition to small molecule discovery, Aurlide has developed a proprietary platform for the de novo design of peptide-based macrocycles, optimal for targeting intracellular protein-protein interactions. As recent highlights, our virtual drug discovery platform has enabled partners to advance an in silico hit to a preclinical candidate in 15 months. Recently, we identified a novel lead series for a challenging ion channel target (patent WO2025017103).